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Background/aim: This study was designed to identify the effect of pentoxifylline on trinitrobenzene sulfonic acid (TNBS)-induced
colitis in rats.
Materials and methods: Forty-two female Wistar rats were randomly divided into 7 groups: group A, TNBS + intraperitoneal (IP)
pentoxifylline; group B, TNBS + IP saline; group C, TNBS + intrarectal (IR) pentoxifylline; group D, TNBS + IR saline; group E, IP
pentoxifylline + TNBS; group F, IP saline + TNBS; group G, IR saline. Pentoxifylline was given daily for 3 days before or 6 days after the
induction of colitis. Rats were killed after 6 days.
Results: IP and IR pentoxifylline similarly and significantly reduced damage and histopathological scores. Pentoxifylline attenuated the
accumulation of malonyldialdehyde and transforming growth factor β1 and the activities of myeloperoxidase, matrix metalloproteinase-3,
and tissue inhibitor of metalloproteinases-1, and it also restored superoxide dismutase activity. The IP route was more effective than the
IR route in this regard. Administration of IP pentoxifylline before or after induction did not influence all parameters.
Conclusions: Pentoxifylline showed a therapeutic effect in this experimental colitis model. IP administration seemed to be better. This
effect may occur as a result of inhibition of oxidative stress and metalloproteinase activity.
Key words: Fibrosis, inflammatory bowel diseases, matrix metalloproteinases, pentoxifylline, transforming growth factor beta, tumor
necrosis factor-alpha

1. Introduction
Inflammatory bowel disease (IBD) is a group of
inflammatory conditions of the colon and small intestine.
Crohn disease (CD) and ulcerative colitis (UC) are the
principal types of IBD. There is evidence that IBD is result
of a genetic predisposition that leads to a mucosal immune
regulatory cell defect and susceptibility to environmental
triggers, particularly luminal bacteria, including specific
antigens and pathogen-associated molecular patterns. An
abnormal relationship is present between innate immune
responses to bacterial structures mediated via toll and
other receptors and the adaptive immune response (1).
Inflammatory cytokines are important mediators
during the development and perpetuation of intestinal
inflammation in IBD. Among these cytokines, tumor
necrosis factor (TNF)-alpha deserves special attention.
Increased concentrations of TNF have been demonstrated
in the feces and intestinal biopsies of patients with IBD
* Correspondence: eylemakbay@hotmail.com
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(2,3). The relationship between TNF-alpha and IBD has
been further supported by the fact that anti-TNF agents
have been a major advance in the management of acutely
ill or corticosteroid-dependent individuals with CD or UC
and in individuals with CD with fistulizing disease (4,5).
On the other hand, the high cost, risk of side effects, and
concern about long-term effects can limit the use of antiTNF-alpha biological agents in the general IBD population.
In this regard, attempts to define other anti-TNF-alpha
agents that could be used as potential treatments are still
ongoing.
Various therapeutic interventions can inhibit the
synthesis or the action of TNF-alpha. Among them,
cyclic AMP (cAMP)-elevating agents have been
shown to suppress TNF-alpha synthesis in murine
macrophages. This observation led to a growing interest
in phosphodiesterase inhibitors, which inhibit the
degradation of cAMP to 5’-AMP, as candidate molecules

KARATAY et al. / Turk J Med Sci
for the treatment of IBD (6,7). In this study, we assessed
the ability of pentoxifylline to attenuate colon damage
and inflammation in a trinitrobenzene sulfonic acid
(TNBS) rat model, an experimental model of colitis that
is characterized by transmural inflammation, ulceration,
and fibrosis resembling CD.
2. Materials and methods
2.1. Animals
Forty-two female Wistar rats weighing 200-250 g were
kept under constant temperature (22 °C) and humidity
with 12-h dark/light cycles and were allowed standard
laboratory animal chow and water ad libitum throughout
the experimental period.
2.2. Induction of colitis and experimental groups
TNBS was used to induce experimental colitis according
to the procedure described by Morris et al. (8). Briefly,
rats fasted for 24 h were anesthetized with ketamine
hydrochloride and an 8-F polyethylene catheter was
inserted rectally until splenic flexure (8 cm from the
anus). Then 30 mg of TNBS (Sigma, France) dissolved
in a volume of 0.15 mL of 50% ethanol was administered
through the catheter. TNBS was retained in the colon for
1 min, after which the fluid was withdrawn. Pentoxifylline
(Hemopene, İbrahim Etem, Turkey) ampoules (100 mg,
5 mL) were mixed with physiological saline solution
and subsequently administered via intraperitoneal (IP)
or intrarectal (IR) route at 100 mg/kg once daily for 3
days before or 6 days after the induction of TNBS colitis.
Control animals received only a vehicle (0.9% saline).
The rats were randomly divided into 7 groups of 6 rats
each: group A, TNBS + IP pentoxifylline; group B, TNBS
+ IP saline; group C, TNBS + IR pentoxifylline; group D,
TNBS + IR saline; group E, IP pentoxifylline + TNBS;
group F, IP saline + TNBS; group G, IR saline.
Rats were killed 6 days after induction of colitis and
the distal 10 cm of the colon was excised, opened by
longitudinal incision. Tissue samples were prepared for
histopathological examination and the remaining mucosa
was immediately snap-frozen in liquid nitrogen and stored
at –80 °C for determination of superoxide dismutase (SOD),
myeloperoxidase (MPO), matrix metalloproteinase-3
(MMP-3), and tissue inhibitor of metalloproteinases-1
(TIMP-1) activities and malonyldialdehyde (MDA) and
TGF-β1 levels.
The study protocol was approved by the Gazi University
Ethics Committee (03/07/20013; G.Ü.ET-13.048).
2.3. Assessment of colitis
Morphological examination was performed by an
experienced pathologist unaware of the experiments being
performed. The macroscopic appearances of the colonic
mucosa were scored on a scale adapted from Morris et al.
ranging from 0 to 4: 0- no macroscopic change; 1- mucosal

erythema alone; 2- mild mucosal edema, slight bleeding,
or small erosions; 3- moderate edema, bleeding ulcers,
or erosions; 4- severe ulceration/erosions, edema, and
tissue necrosis (8). For microscopic examination tissue
samples were fixed in phosphate-buffered formaldehyde
and embedded in paraffin, and routine 5-µm sections were
prepared. Tissues were routinely stained with hematoxylin
and eosin and were evaluated by light microscopy. The
microscopic appearances of the colonic mucosa were
scored on a scale adapted from Ackerman et al. (9):
A: Depth of necrosis: none = 0; mucosal = 1; mucosal
and submucosal = 2; mucosal, submucosal, and muscularis
propria = 3; full thickness = 4.
B: Extent of necrosis: none = 0; small area = 1; moderate
area = 2; large area = 3; extensive = 4.
C: Inflammation: none = 0; minimal = 1; mild = 2;
moderate = 3; severe = 4.
D: Extent of inflammation: none = 0; mucosal = 1;
mucosal and submucosal = 2; mucosal, submucosal, and
muscularis propria = 3; full thickness = 4.
The scores for each category examined were calculated
for each specimen in the different groups. These were then
added to obtain the total score, which was then divided
by the number of rats’ colons examined in each group to
obtain the average histologic score of induced colitis for
the group.
2.4. Assessment of tissue biomarkers
The sample tissues were homogenized (50 g/L) in 50
mmol/L ice-cold potassium phosphate buffer (pH
6.0) containing 0.5% hexadecyltrimethylammonium
bromide. The homogenate was frozen and thawed thrice,
then centrifuged at 15,000 rpm for 15 min at 4 °C. The
MPO activity in the supernatant was measured by assay
kit (Eastbiopharm, China) according to the provider’s
instructions. The MDA contents and SOD activities in the
supernatant were also measured by assay kit (Eastbiopharm)
according to the provider’s instructions. TGF-β1 levels
and TIMP-1 and MMP-3 activities (Eastbiopharm) were
assessed by ELISA technique according to the provider’s
instructions.
2.5. Statistical analysis
All statistical analyses were performed with SPSS 11.5 for
Windows (SPSS Inc., USA). Normality was assessed using
the Shapiro–Wilk test. Accordingly, data were expressed
as median (min–max). Because data were not normally
distributed and the number of tested subjects were less
than 30 in each group, nonparametric tests were preferred:
the Kruskal–Wallis test for comparison of multiple groups
and the Mann–Whitney test to compare two groups.
Correlation of tissue biomarkers with each other and
histological scores were assessed using Spearman rank
correlations. A two-sided P-value of 0.05 or less was
considered statistically significant.
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3. Results
There was no mortality in animals with colitis. Severe
macroscopic inflammation was observed 6 days after
intrarectal application of TNBS. Administration of
intraperitoneal or intrarectal pentoxifylline similarly and
significantly reduced the macroscopic damage severity
(Table 1). The colon from sham-treated rats had a normal
microscopic appearance. The colon from rats that had
been treated with TNBS had inflammatory findings
as follows: mucosal edema, necrosis, abnormal crypt
architecture, mural thickening of the colon, and intense
polymorphonuclear reaction. Intraperitoneal or intrarectal
pentoxifylline similarly and significantly attenuated the
microscopic damage severity (Table 1; Figure 1).
Significantly increased MPO activity was observed 6
days after TNBS application. Treatment with pentoxifylline
attenuated the accumulation of MPO in the colons of rats
exposed to TNBS (Table 2; Figure 2).
Compared with those of the sham-treated rats, the
contents of MDA, TGF-β1, MMP-3, and TIMP-1 in
colonic tissues were significantly increased in rats with
TNBS-induced colitis (Tables 2 and 3). Pentoxifylline
attenuated the accumulation of MDA and TGF-β1 and
the activities of MMP-3 and TIMP-1 (Tables 2 and 3).
Compared with the sham-treated rats, SOD activity was
significantly decreased in the colonic tissue of rats exposed
to TNBS. SOD activity showed restoration to normal levels
after pentoxifylline (Table 2) (Figure 3-7).

Although improvement in macroscopic and
microscopic damage was similar between IP and IR
pentoxifylline, the IP route was more effective than the
IR route at decreasing the accumulation of MPO, MDA,
TIMP-1, MMP-3, and TGF-β1 and restoring SOD activity
to normal levels in rat colonic tissues (Tables 2 and 3).
There was no difference between the pathological scores
and tissue biomarkers of inflammation and fibrosis with
respect to administration of IP pentoxifylline before or
after induction of TNBS colitis (Tables 2 and 3).
4. Discussion
This study described the effect of administration of
pentoxifylline on the macroscopic and microscopic
damage scores of rat colons. The results of histopathological
examination indicated that a significant difference was
found between rats that had been treated with TNBS and
control rats, and pentoxifylline successfully attenuated
inflammation and ulcers caused by intracolonic TNBS.
The healing effect was obtained from both intraperitoneal
and intracolonic administration. These results suggest that
pentoxifylline may find application in the treatment of
IBD in humans.
The influence of pentoxifylline on the severity of
gut inflammation has been examined previously in
several animal models of IBD (10). Pentoxifylline and
its metabolite-1 significantly attenuated colon damage
and inflammation in an animal model of TNBS-induced

Table 1. Effect of treatment with intraperitoneal or intrarectal pentoxifylline on macroscopic and microscopic pathological
scores of colonic tissue from rats with TNBS-induced colitis.
Macroscopic scores

Microscopic scores

Group A
TNBS + IP pentoxifylline

1 (1–2)

5 (4–8)

Group B
TNBS + IP saline

4 (3–4)

14 (12–14)

Group C
TNBS + IR pentoxifylline

1 (1–2)

7 (6–8)

Group D
TNBS + IR saline

3.5 (3–4)

13 (12–14)

Group E
IP pentoxifylline + TNBS

2.5 (1–3)

8 (4–8)

Group F
IP saline + TNBS

4 (3–4)

14 (12–14)

Group G
IR saline

0 (0–0)

0 (0–0)

P-value

Groups compared

<0.001
>0.05
>0.05

A vs. B
A vs. C
A vs. E

<0.001

C vs. D

<0.001

E vs. F

Scores are expressed as median (min–max). TNBS: Trinitrobenzene sulfonic acid. P < 0.05 when all of the individual groups
were compared with group G for macroscopic and microscopic scores.
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*P < 0.001
** P < 0.001
*** P < 0.001
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Figure 1. Effect of treatment with intraperitoneal or intrarectal pentoxifylline on macroscopic and microscopic pathological
scores of colonic tissue from rats with TNBS-induced colitis.
Table 2. Effect of treatment with pentoxifylline on various tissue biomarkers of inflammation from rats with TNBS-induced colitis.
MPO
(U/g)

MDA
(µmol/g)

SOD
(U/g)

Group A
TNBS + IP pentoxifylline

0.18
(0.16–0.19)

1.2
(0.9–1.3)

163
(162–164)

Group B
TNBS + IP saline

0,70
(0.63–0.80)

4.3
(3.4–54)

144
(143–145)

Group C
TNBS + IR pentoxifylline

0.27
(0.26–0.29)

2.3
(1.9–2.5)

157
(155–158)

Group D
TNBS + IR saline

0.60
(0.52–0.65)

3.9
(3.2–4.5)

143
(142–144)

Group E
IP pentoxifylline + TNBS

0.36
(0.35–0.41)

2.9
(2.4–3.2)

153
(149–153)

Group F
IP saline + TNBS

0.57
(0.48–0.66)

5.8
(5.1–7)

138
(136–141)

Group G
IR saline

0.17
(0.1–0.21)

1.6
(1–2.8)

159
(150–162)

<0.001
<0.001
<0.05
<0.05a
<0.05

Groups
compared
A vs. B
A vs. C
A vs. E
A vs. G
B vs. G

<0.001
<0.05b
<0.05

C vs. D
C vs. G
D vs. G

<0.001
<0.05
<0.05

E vs. F
E vs. G
F vs. G

P-value

TNBS: Trinitrobenzene sulfonic acid, MPO: myeloperoxidase, MDA: malonyldialdehyde, SOD: superoxide dismutase. Scores are
expressed as median (min–max). aOnly SOD showed a significant difference. bOnly MPO showed a significant difference.

colitis. Metabolite-1 treatment significantly reduced the
TNBS-induced increase in colon weight, colon thickness,
and total collagen content, supporting its antifibrotic

potential (10). In another study, pentoxifylline treatment
was not sufficient to reduce the elevation in colonic
collagen, although the treatment was sufficient to reduce
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Table 3. Effect of treatment with pentoxifylline on various tissue biomarkers of fibrosis from rats with TNBS-induced colitis.
TIMP-1
(ng/g)

MMP-3
(ng/g)

TGF-β1
(ng/g)

Group A
TNBS + IP pentoxifylline

10.3
(9.3–11.2)

75
(70–89)

1.3 (0.8–1.4)

Group B
TNBS + IP saline

20.1
(18.3–26.5)

165
(163–168)

4.9 (4.2–5.8)

Group C
TNBS + IR pentoxifylline

13.6
(12.9–14.7)

101
(93–114)

2.4 (2–2.5)

Group D
TNBS + IR saline

19.1
(18.2–21.8)

164
(163–168)

4.8 (4–5.6)

Group E
IP pentoxifylline + TNBS

15
(14.5–16.9)

130
(122–138)

2.8 (2.7–3.8)

Group F
IP saline + TNBS

27
(22.8–28.9)

166
(162–188)

5.7 (5.2–6.8)c

Group G
IR saline

7.8
(6.5–10.9)

33 (15–53)

1 (0.6–1.5)

P-value

Groups
compared

<0.001
<0.001
<0.05
<0.05a
<0.05

A vs. B
A vs. C
A vs. E
A vs. G
B vs. G

<0.001
<0.05
<0.05

C vs. D
C vs. G
D vs. G

<0.001
<0.05
<0.05

E vs. F
E vs. G
F vs. G

TNBS: Trinitrobenzene sulfonic acid, TIMP-1: tissue inhibitor of metalloproteinases-1, MMP-3: matrix metalloproteinase-3, TGF-β1:
transforming growth factor β1. Scores are expressed as median (min–max). aOnly TIMP-1 and MMP-3 showed a significant difference.

Group A: TNBS + IP pentoxifylline
*P<0.001
* *P<0.001
***P<0.001

Group B: TNBS + IP saline,

MPO
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Figure 2. Effect of treatment with pentoxifylline on MPO levels of inflammation from rats with TNBS-induced colitis.

the pathological changes due to TNBS, raising a question
about the antifibrotic potential of the treatment (11).
Murthy et al. observed that pentoxifylline in combination
with a single injection of TNF-alpha monoclonal antibody
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was significantly more effective in inhibiting the disease
severity, ulcer index, and inflammation compared to a
placebo or any single monotherapy in dextran sulfateinduced mouse colitis (12).
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*P < 0.001
**P < 0.001
***P < 0.001
# P < 0.05
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Figure 3. Effect of treatment with pentoxifylline on MDA levels of inflammation from rats with TNBS-induced colitis.
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* *P < 0.001
***P < 0.001
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Figure 4. Effect of treatment with pentoxifylline on MMP-3 levels of inflammation from rats with TNBS-induced colitis.

So far, only two studies on this topic have included
human subjects (13,14). Peripheral mononuclear cells
(PBMCs) and inflamed intestinal mucosa from patients

with IBD release various inflammatory mediators (13).
The first of the above-mentioned studies carried out in
IBD patients showed that pentoxifylline attenuated the
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Figure 5. Effect of treatment with pentoxifylline on TIMP-1 levels of inflammation from rats with TNBS-induced colitis.
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Figure 6. Effect of treatment with pentoxifylline on TGF-β1 levels of inflammation from rats with TNBS-induced colitis.

production of TNF-alpha by PBMCs and the release of
TNF-alpha and interleukin-1 by organ cultures of inflamed
intestinal mucosa (13). However, inhibition of TNF-alpha
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production by pentoxifylline in a group of patients with
steroid-dependent CD was not successful in improving
clinical, endoscopic, or laboratory parameters (14). There
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* *P < 0.001
***P < 0.001
#P < 0.05
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Figure 7. Effect of treatment with pentoxifylline on SOD levels of inflammation from rats with TNBS-induced colitis.

is no satisfactory explanation for this observation but it
is already known that blocking TNF-alpha does not turn
off the inflammatory cascade in approximately 25% of
patients (15). Another consideration is that the patients in
the above-mentioned study were mildly active CD patients
receiving low-dose steroid therapy. The absence of severe
baseline inflammation might have partially accounted for
lack of antiinflammatory response to pentoxifylline.
To uncover the mechanisms responsible for the
mucosal improvement with pentoxifylline, we measured
several tissue biomarkers. MPO is a proinflammatory
enzyme present in the azurophilic granules of neutrophilic
granulocytes and it serves to quantify neutrophil
accumulation in tissues (16). Lipid peroxidation, a
type of oxidative degeneration of polyunsaturated fatty
acids, is associated with altered membrane structure
and decreased activity of antioxidant enzymes. We
measured MDA, an end-product of lipid peroxidation,
as an indicator of this pathological process (17). Animal
studies provide evidence for the critical role of TGF-β1
in triggering and sustaining intestinal fibrogenesis (18).
MMPs are involved in the remodeling and degradation
of the extracellular matrix and they were increased in
inflamed colons of patients with IBD (19). Lastly, SOD
was measured in our study because it is a primary defense
against oxidative stress, mediating intestinal damage in
IBD (20). The finding that pentoxifylline prevented an
increase in MPO, MMP-3, and TIMP-1 activities and the
accumulation of MDA and TGF-β1 supports the concept
of an inhibition of inflammatory response, oxidative stress,

and tissue remodeling as pentoxifylline’s contribution to
the attenuation of macroscopic and microscopic colonic
damage. The restoration of SOD activity to normal levels
following the administration of pentoxifylline is also
consistent with its antioxidant potential.
Another important finding of our study was that
administration of pentoxifylline prior to TNBS was partially
successful to protect against the development of colitis.
This may suggest a role for pentoxifylline in postoperative
prophylaxis of CD. Why was intraperitoneal pentoxifylline
more effective compared to intrarectal pentoxifylline?
TNBS, associated with transmural inflammation, more
closely mimics CD. Although topical agents such as 5-ASA
may be used in colonic CD, there is reason to question the
rationale for using a superficially active antiinflammatory
agent in a transmural disease (21). This study suggests
that inferior response to intrarectal pentoxifylline might
have resulted from a more superficial inflammation in the
relevant rats. The efficacy of intraperitoneal pentoxifylline
in our study suggests a role for this drug in CD patients
with penetrating disease behavior.
In conclusion, the findings of this research indicate
that pentoxifylline therapy alters the course of TNBS
colitis and results in histological improvement. Decreased
oxidative stress and inhibition of cytokine release and
inflammatory response may contribute to the therapeutic
effects of pentoxifylline. Further research is required
to provide evidence of the potential of this drug as an
antiinflammatory and antifibrotic agent in IBD.
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